Drugmakers Kaleo, Impax Labs Withdraw Patents Challenged by FTC; GlaxoSmithKline Takes on Legal Risk by Recertifying a Listing

Published on Dec 15, 2023

After receiving notice letters from the Federal Trade Commission last month disputing certain drug patents, drugmakers Kaleo, Impax Laboratories (IPXL) and GlaxoSmithKline (GSK) have responded by withdrawing or recertifying challenged patent listings from the Orange Book, the Food and Drug Administration’s publication of approved drug products. In November 7 letters to Kaleo, Impax Laboratories, GlaxoSmithKline […]

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2024 The Capitol Forum. All Rights Reserved.